Consolidated Financial Results (Tanshin)
for the Six Months Ended September 30, 2026 (Based on IFRS)

November 12, 2026

Name of listed company	:CYBERDYNE, INC.	Stock exchange listing	:Growth Section of TSE
Stock code	:7779	URL	:https://www.cyberdyne.jp/english
Representative (title)	:President and CEO	Name	:Yoshiyuki Sankai
Contact (title)	:Director and COO	Name	:Shinji Honda Tel. +81-29-869-9981
Scheduled date for release of six-month report		:November 12, 2026	Scheduled start of dividend payment :—
Additional materials for the financial results		:yes	
Information meeting for the financial results		:yes (only for institutional investors)	

(Millions of yen: Rounded to the nearest one million yen)

I. Consolidated financial results for the six months ended September 30, 2026 (April 1, 2026-September 30, 2026)

1. Consolidated result of operations (percentages denote year-on-year change)

	Revenue		Operating profit (loss)		Profit (loss) before tax		Profit (loss) attributable to owners of parent	
		%		%		%		%
Apr.1-Sep. 30, 2026	2,008	2.3	(124)	—	170	(42.9)	54	(22.5)
Apr.1-Sep. 30, 2025	1,963	(8.4)	(174)	—	297	—	70	—

	Basic earnings (loss) per share	Diluted earnings (loss) per share
	Yen	Yen
Apr.1-Sep. 30, 2026	0.26	0.26
Apr.1-Sep. 30, 2025	0.33	0.33

2. Consolidated financial position

	Total assets	Total equity	Total equity attributable to owners of the parent	Ratio of equity attributable to owners of the parent to total assets
	Millions of yen	Millions of yen	Millions of yen	%
As of Sep. 30, 2026	49,208	39,831	39,845	81.0
As of Mar 31, 2026	49,081	39,609	39,622	80.7

II. Dividends

	Dividend payments for each term and the year				
	End of 1st quarter (June.30)	End of 2nd quarter (September.30)	End of 3rd quarter (December.31)	Fiscal year end (March.31)	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	—	0.00	—	0.00	0.00
Fiscal year ending March 31, 2027	—	0.00			

Notes:

(i) Changes from the latest released dividend forecasts: none

(ii) The table of “Dividends” indicates dividend payments on Common Shares. Dividends on Class Share (non-listed) for which the number of share units differs from Common Shares are shown below as “Dividends on Class Shares”.

III. Forecast of consolidated financial results for the fiscal year ending March 31, 2027 (April 1, 2026-March 31, 2027)

As the business of CYBERDYNE Inc. and its group companies (collectively referred to as the “Group”) is based on a new market with innovative technologies, there are many uncertain factors that could have an impact on its performance and make it difficult for CYBERDYNE Inc. (the "Company") to provide a forecast with accurate figures. As such the Company will not announce the forecast of consolidated financial results.

Notes:

1. Changes in key subsidiaries during the consolidated six month period (changes in specific subsidiaries resulting in changes of consolidation scope): none

   new: － (company name: －) , excluded: － (company name: －)

2. Changes in accounting policies, accounting estimates, and restatement of error corrections

   (i) Changes in accounting policies required by IFRS : none

   (ii) Changes in accounting policies due to reasons other than (i) : none

   (iii) Changes in accounting estimates: none

3. Total number of issued shares (Common Shares)

   (i) Total number of issued shares at the end of each period (including treasury shares)

As of September 30, 2026	215,145,809 shares	As of March 31, 2026	215,145,809 shares

   (ii) Total number of treasury shares at the end of each period

As of September 30, 2026	4,014,854 shares	As of March 31, 2026	4,014,804 shares

   (iii) Average number of shares during each six month period

Apr.1-September 30, 2026	211,130,955 shares	Apr.1-September 30, 2025	211,131,056 shares

   Note: Class B Shares are ranked the same as Common Shares and paid the same amount as Common Shares with regard to dividends of surplus and distribution of residual assets. Therefore the total number of issued shares at each end of period and the average number of shares during each period include Class B Shares as Common Shares.

*This quarterly consolidated financial report is not subject to the quarterly review procedure by the scope of audit.

Dividends on Class Shares

Details of dividends on the Company's class shares for which the number of share units differs from its Common Shares are as below.

	Dividend payments for each term and the year				
	End of 1st quarter (June.30)	End of 2nd quarter (September.30)	End of 3rd quarter (December.31)	Fiscal year end (March.31)	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	—	0.00	—	0.00	0.00
Fiscal year ending March 31, 2027	—	0.00			

Note:

The Company issued Class B Shares which were accorded the same rights as its Common Shares with regard to dividends and distribution of residual assets, but for which share units differ from Common Shares.

○ Contents of the Attached Material

1. Qualitative information regarding settlement of accounts for the six months.…… 2
(1) Explanation of operating results.…… 2
(2) Explanation of financial position…… 6
(3) Status of cash flow..…… 7
2. Condensed quarterly consolidated financial statement (Unaudited) …… 8
(1) Condensed quarterly consolidated statement of financial position (Unaudited)…… 8
(2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income (Unaudited)...…….. 10
Condensed year to quarter end consolidated statement of profit or loss…… 10
Condensed year to quarter end consolidated statement of comprehensive income...…… 11
(3) Condensed quarterly consolidated statement of changes in equity (Unaudited)…… 12
(4) Condensed quarterly consolidated statement of cash flows (Unaudited)...…… 14
(5) Notes to condensed quarterly consolidated financial statements…… 15
(Notes on premise of going concern) …… 15
(Segment information) …… 15
(Revenue) ..…… 16

1. Qualitative information regarding settlement of accounts for the six months ended September 30, 2026

(1) Explanation of operating results

All forward-looking statements included in this explanation were determined reasonable by CYBERDYNE Inc. (the "Company") and its group companies (collectively referred to as the "Group") based on currently available information for the consolidated six-month period ended September 30, 2026, and certain assumptions made by the Group.

To solve the complex and structural challenges facing society in a super-aging era, the Group leverages "HCPS-integrated Cybernics with Physical AI," which fuses bio/medical systems with AI robots and information systems, as its core technologies. Through these technologies, the Group aims to realize a well-being-oriented future society, the "Techno Peer Support Society," in which people and technology coexist and mutually support one another, enabling all people—regardless of age or disability—to enhance their independence and freedom while solving physical, mental, and lifestyle-related challenges and living with peace of mind. At the same time, the Group is leading the creation of the "Cybernics Industry," a new industry following the robotics and IT industries.

Status of business operation

To realize the Techno Peer Support Society and create the Cybernics Industry, the Group conducts its business through two core solution: "Cybernics Medical and Healthcare Innovation," which comprehensively addresses medical care and health through collaboration and fusion between the medical and non-medical fields, and "Cybernics Life Innovation," which supports the movement and work of people and objects.

(Cybernics Treatment)

The Group is working to promote Cybernics Treatment using HAL®, the world's first wearable cyborg and a representative Physical AI product of the Company, to facilitate the improvement and regeneration of brain, nerve, and muscular functions, and to establish it as a global standard treatment.

In a systematic review published in 2025 in the international medical journal Global Spine Journal, HAL was compared with nine other passively controlled exoskeleton-type devices of similar form (devices that repeatedly perform movements through robotic control). The results demonstrated that HAL is the only device that induces neuroplasticity and provides comprehensive therapeutic effects across multiple health outcomes associated with spinal cord injury (SCI). The paper cites findings from functional MRI studies, which report that active movement elicits significantly greater neural activity in the central nervous system than passive movement. Furthermore, it discusses that the repetitive neuromuscular process established between the central and peripheral nervous systems—made possible by HAL's core principles—facilitates the learning and reinforcement of neural signaling in the brain and spinal cord, ultimately leading to the reconstruction and reactivation of spinal circuits below the site of spinal cord injury and the partial reinnervation of neural pathways. Through this mechanism of inducing neuroplasticity, HAL demonstrated consistent improvement not only in primary mobility outcomes such as walking distance and speed but also in secondary outcomes such as urinary and bowel function (continence), pain reduction, and overall quality of life (QoL). These findings provide clinical evidence that HAL is a unique therapeutic device offering a comprehensive treatment approach to the entire neuromuscular system.

In June 2026, the Company began rental sales in Japan of a new Medical HAL Lower Limb Type model, positioned as a core model for accelerating the adoption of Cybernics Treatment. A single unit accommodates users approximately 150 cm to 190 cm tall and offers significantly improved operability and ease of deployment. The Company plans to roll out the new model overseas in stages.

(Nursing Care and Independent Living Support)

The Group has developed various types of HAL for seniors to improve their physical function, prevent frailty and age-related functional decline, and reduce the requirement for care. These include the HAL Lower Limb Type for enhancing the ability to walk, the HAL Single Joint Type to train elbow, knee, and ankle movements, and the HAL Lumbar Type to train the trunk function.

In the "ME-BYO" cohort study conducted in Kanagawa Prefecture, a preventive care program utilizing the HAL Lumbar Type demonstrated effectiveness in maintaining health and improving physical function among

elderly participants (*). Based on these research findings, the Group is promoting the expansion of health promotion and frailty prevention programs both in Japan and overseas.

(*) In a study of 79 elderly individuals diagnosed with frailty or pre-frailty who participated in a five-week exercise program (twice weekly), the HAL group showed a 36% improvement in 10-meter walking speed and a 93% improvement in Locomo score compared to baseline, indicating significant improvement in mobility function.

(Prevention and Early Detection)

The Company is developing and commercializing the "Cyvis" series, which collects, analyzes, and AI-processes medical and healthcare data daily to provide optimized health management, disease prevention, diagnosis, and treatment programs tailored to each individual. One of the products in this series, the "Compact Holter ECG Medical Vital Sensor Cyvis M100," aims to prevent stroke and dementia—including vascular dementia caused by stroke, which together represent the two leading causes requiring nursing care—by enabling the early detection and treatment of arrhythmias such as atrial fibrillation. In September 2026, as the first commercial rollout of the Cyvis series, the Company launched a Holter ECG testing support service for medical institutions using Cyvis M100. Healthcare professionals can access measurement data and analysis results through a dedicated website, reducing the operational burden of conventional Holter ECG testing, including data collection and review, while supporting extended ECG monitoring for more than seven days. Cyvis can measure not only cardiac activity data but also body surface temperature and acceleration, etc. Operational verification is underway not only for medical institutions but also for welfare facility residents and workers. The Company plans to gradually expand the items measured. Furthermore, the Company will continue to develop and commercialize new devices capable of collecting other medical and healthcare data.

The Group develops “Acoustic X”, a patented photoacoustic imaging system based on the LED light source method that realizes real-time, high-resolution 3D imaging of blood vessels and blood in the peripheral organs without needing contrast agents. The Group develops this technology as a next-generation medical image diagnosis device. In addition, research is underway at prominent medical institutions and research facilities around the globe to create various applications for this technology.

(Work Assistance and Labor-Saving Solutions)

Sales of the new model (LB06) of the HAL Lumbar Type for Work Support, which supports both reducing physical workload for workers and improving safety and productivity, began in Japan in February 2026. Compared to the previous model, it achieves easier wearing, lighter weight, and a slimmer design, and is expected to be utilized in a wide range of work sites involving heavy-duty tasks, such as emergency rescue operations, airports, factories, construction, logistics, and agriculture.

Regarding the next-generation Cleaning Robot CL02, which uses cutting-edge SLAM technology to achieve high-speed autonomous driving, the Group works with major construction companies with its ability to ride on elevators automatically and connect with cloud systems; the companies are developing this technology as a solution to make building management smarter and reduce management costs. Furthermore, the company is expanding its mobility part as a transportation robot inside the factory.

(Regional status : Japan)

The Group continues to develop Cybernics Treatment for progressive neuromuscular disease patients where there is no established treatment method. Post-marketing surveillance on the Medical HAL Lower Limb Type Double-leg Model suggested an extremely high efficacy and safety towards progressive neuromuscular diseases, for which no effective treatment methods have been established. Based on the results above, Medical HAL Lower Limb Type was given increased points after the 2022 revision of medical treatment fees as “a remarkable functional improvement effect unprecedented in patients with progressive neuromuscular diseases for which no other effective treatment methods have been established, including already approved drugs” (excerpt from the medical technology evaluation proposal by the Japanese Society for Neurological Therapeutics).

Regarding spinal cord-related diseases, the Japanese Minister of Health, Labor, and Welfare (“MHLW”) approved additional indications of HTLV-1-associated myelopathy (HAM) and hereditary spastic paraplegia for HAL in October 2022 and public health insurance has been available since October 2023. Regarding traumatic spinal cord injuries, the Company is consulting with the regulators on the necessary steps to obtain

approval for additional indications.

Regarding stroke, based on the results of the investigator-initiated clinical trial using the Medical HAL Lower Limb Type single-leg model (HIT2016 trial) and the latest patient profile and clinical needs, the Company is preparing to submit a clinical trial notification for a trial using the new model of the Medical HAL Lower Limb Type Double-leg model.

In January 2025, the small-size model of the Medical HAL Lower Limb Type was approved as a medical device for the same target diseases as the conventional model. With the approval of this small-size HAL, Cybernics Treatment has become available for patients with an estimated height of 100 cm to 150 cm, who previously had difficulty using the conventional model (intended for those 150 cm or taller).

Based on favorable results in a pilot study demonstrating improved motor function in patients with Parkinson's disease, the Company is preparing to conduct clinical trials for the approval of HAL “Lumbar Type” as a medical device.

In the Nursing Care and Independent Living Support area, the Group operates the Robocare business, providing Neuro HALFIT, a program that induces improvement of the brain-nerve and musculoskeletal system through utilizing HAL. As a hub for individual-oriented medical and healthcare services, the program is developed in collaboration with the Group and regional business partners. In addition, as a home-based service for individuals, the Group offers “Neuro HALFIT at Home”, a home-based program in which individual customers rent HAL and engage in “Neuro HALFIT” at home.

(Regional status : USA)

Currently, Medical HAL has obtained approval from the U.S. FDA for spinal cord injury, stroke, eight progressive neuromuscular diseases, cerebral palsy (age 12 and older), HTLV-1 associated myelopathy (HAM), and hereditary spastic paraplegia as target indications. Based on these approvals, the Company develops its business through both individual medical service offerings and product rental services for Medical HAL.

As a medical service platform for individuals, the Company’s subsidiary, RISE Healthcare Group (RHG), operates mainly in Southern California, with five facilities offering Cybernics Treatment using HAL.

In December 2025, the Company concluded a strategic Memorandum of Understanding (MoU) with Carnegie Mellon University, a world-leading U.S. institution in AI and robotics research, to promote collaboration in research and education in the rapidly advancing field of Cybernics—which integrates bio/medical systems with AI, robotics, and information systems—and to accelerate the societal implementation in the United States of both the Company’s existing products and future products. Under the MoU, the Company is preparing to work with the Pittsburgh medical and healthcare ecosystem in support of this collaboration and implementation.

In June 2026, the Company also commenced a strategic business alliance with Pegasus Tech Ventures, Inc., a global venture capital firm based in Silicon Valley, USA. By strengthening access through Pegasus to promising startups, advanced technologies, and innovation ecosystems around the world, the Company will promote technology development and business co-creation in the area of “HCPS-integrated Cybernics with Physical AI,” create new business opportunities, and expand its business in global markets.

(Regional status : EMEA - Mainly Europe and the Middle East)

The Group continues to expand Cybernics Treatment in major countries such as Germany, Italy and Turkey.

In Ukraine, in November 2024, the Company received an order for HAL series and other Cybernics products as part of the Ukraine Emergency Recovery and Reconstruction Project implemented by the Japan International Cooperation Agency (JICA), and delivery for installation at a medical facility in Kyiv, Ukraine’s capital, has been completed. In addition to this project, the Company was selected in October 2025 for a publicly solicited project under the “Ukraine Reconstruction Support and Strengthening Cooperation with Central and Eastern European Countries Project” promoted by the Ministry of Economy, Trade and Industry of Japan (METI), and in December 2025 for a publicly solicited project under the “Green Industrial Recovery Project for Ukraine” promoted by the United Nations Industrial Development Organization (UNIDO). Through these initiatives, the Company is promoting efforts to support the social reintegration of war-injured individuals and the restoration of medical infrastructure.

In Germany, a clinical trial aimed at obtaining public health insurance coverage for spinal cord injury treatment has commenced pursuant to a decision by the G-BA (German Federal Joint Committee), the

decision-making body for the public health insurance system. Treatment of the first patient began in August 2026. In addition, a public health insurance reimbursement rate of EUR 334.71 per session has been officially set for the use of HAL in this clinical trial.

(Regional status : APAC - Asia Pacific)

With CYBERDYNE MALAYSIA, the Group's Malaysian subsidiary, as its base, the Group continues to promote Cybernics Treatment across Southeast Asia, India, Australia, and Taiwan.

In Malaysia, the partnership with the government-affiliated Social Security Organization (PERKESO) has been further strengthened, expanding access to Cybernics Treatment with HAL under PERKESO insured persons. In June 2026, the National Neuro-Robotics and Cybernics Rehabilitation Centre, one of the largest integrated medical facilities in Southeast Asia, officially opened. The Company has installed 50 sets (65 units) of HAL at the facility under a large-scale installation contract with PERKESO. PERKESO has also officially announced plans to construct a new center as the next project for the facility, and discussions are underway regarding the introduction of HAL to this new center.

In Thailand, based on the results achieved in Japan through preventive care programs utilizing the HAL Lumbar Type, the Company reached an agreement in January 2026 with the Institute of Geriatric Medicine under the Ministry of Public Health to jointly promote "Cybernics Medical and Healthcare Innovation" in ASEAN, and preparations for collaboration are underway.

In Taiwan, following MOU for international collaboration concluded with National Taiwan University and the University of Tsukuba, in November 2025, a symposium on Cybernics Medical and Healthcare Innovation was co-hosted with National Taiwan University, and preparations are underway to further promote the business development in the region.

Status of Research and Development

The proposal of the Group was selected in 2023 for the next Cross-ministerial Strategic Innovation Promotion Program (SIP) Third Phase: Development of Fundamental Technologies, the Establishment of Common Systems, Rules, and Regulations for the Expansion of Human Collaborative Robotics, Theme 6: Development of Social Implementation Technologies for HCPS* Integrated Human Collaborative Robotics to Solve Social Issues" that is led by the Cabinet Office of Japan. Under this program, the Group continues to (i) develop an application for various living spaces such as residences, facilities, and workplaces, (ii) utilize HCPS-integrated Cybernics master remote control technology that works together with human information (physiological, physical, behavioral, cognitive, psychological, etc.), (iii) acquire and utilize human information obtained through non-invasive HCPS-integrated human-collaborative robotics, and (iv) Establish links with other related technologies of the R&D theme to improve the independence and freedom of seniors and people with limited access to transportation.

At the Tonomachi International Strategic Zone (King Sky Front) in Kawasaki City, Cybernics Medical Innovation Base Building A functions to promote the systematization of Cybernics Treatment by combining HAL with regenerative medicine and drugs and the development of technologies that integrate medical and bio-related technologies with AI, robotics and information systems. In anticipation of future business synergies, the Company is promoting the occupancy of life science companies and will continue coordinating with its C-Startup partners in regenerative medicine and drug creation.

Numbers of operating units

Mainly due to an increase in rentals to the APAC region, as of the end of September 2026, 575 Medical HAL Lower Limb Type units were operating worldwide, including those used for clinical research. 113 units were used in Japanese hospitals for treatment. In addition, there were 729 units of HAL Single Joint Type, mainly from the increase of products for medical use. 342 units of HAL for Well-being Lower Limb Type and HAL for Living Support Lower Limb Type (older model) were in operation. Furthermore, 940 units of HAL Lumbar Type for Well-being were in operation. In addition, there were 428 units of HAL Lumbar Type for Labor Support and 179 units of Cleaning Robots and Transportation Robots.

In the consolidated six months that ended September 30, 2026, due to increased sales from product rentals

and other services in Japan and APAC and treatment services and other services in the USA, the revenue recorded at ¥2,008 million (2.3% increase year on year). In addition, the Group recorded a gross profit of ¥1,176 million (3.7% decrease year on year).

The Group recorded research and development expenses at ¥366 million (16.3% decrease year on year), mainly due to developing new products at the Company's own cost, clinical research, and consigned research projects, continuing from the previous fiscal year. In addition, the Group recorded other selling, general, and administrative expenses at ¥1,175 million (1.1% decrease year on year) due to a reduction in expenses.

Other income was recorded at ¥260 million (8.5% decrease year on year), mainly due to exchange gains and a consigned research project, resulting in an operating loss of ¥124 million (28.5% decrease year on year).

The Group recorded a finance income of ¥410 million, mainly due to gains on the valuation difference of investment securities, including the valuation gain on the fund disclosed in the announcement dated June 1, 2026, regarding the strategic business alliance and joint promotion of strategic investment activities with Pegasus Tech Ventures, Inc., as well as interest income. In addition, the Group recorded gains related to CEJ Fund at ¥8 million and income tax expense at ¥116 million from deferred tax expenses, resulting in the posting of profit attributable to owners of the parent at ¥54 million (22.5% decrease year on year).

(2) Explanation of financial position

① Assets

For the consolidated six months ended September 30, 2026, assets increased ¥127 million to ¥49,208 million compared to the end of the previous fiscal year. Changes were mainly due to a decrease of ¥5,010 million in other financial assets (current), partially offset by an increase of ¥3,865 million in cash and cash equivalents and ¥1,378 million in other financial assets (non-current).

② Liabilities

For the consolidated six months ended September 30, 2026, liabilities decreased ¥95 million to ¥9,378 million compared to the end of the previous fiscal year. The changes were mainly due to a decrease of ¥268 million in Third-party interests in CEJ Fund and ¥100 million in trade and other payables, partially offset by an increase of ¥224 million in deferred tax liabilities.

③ Equity

For the consolidated six months ended September 30, 2026, equity increased ¥222 million to ¥39,831 million compared to the end of the previous fiscal year. This was due to gains on valuation of financial assets measured at fair value through other comprehensive income, among other factors.

(3) Status of cashflow

For the consolidated six months ended September 30, 2026, cash and cash equivalents increased ¥3,865 million to ¥12,855 million compared to the end of the previous fiscal year. The main influence factors for the cash flow status within the consolidated six months ended September 30, 2026, are stated below.

(Cash flows from operating activities)

For the consolidated six months ended September 30, 2026, net cash used in operating activities recorded an outflow of ¥44 million (an inflow of ¥362 million in the previous consolidated six months). Changes were mainly due to depreciation and amortization at ¥307 million and profit before tax recorded at ¥170 million, partially offset by finance income posted at ¥410 million.

(Cash flows from investment activities)

For the consolidated six months ended September 30, 2026, net cash provided by investing activities recorded an inflow of ¥4,063 million (an outflow of ¥2,794 million in the consolidated six months of the previous fiscal year). The changes were mainly due to the proceeds of redemption of investments posted at

¥5,000 million, partially offset by the purchase of investment securities posted at ¥833 million.

(Cash flows from financing activities)

For the consolidated six months ended September 30, 2026, net cash used in financing activities recorded an outflow of ¥146 million (an outflow of ¥97 million in the consolidated six months of the previous fiscal year). The changes were mainly due to the outflow of ¥97 million from Lease liabilities paid.

2. Condensed quarterly consolidated financial statement

(1) Condensed quarterly consolidated statement of financial position (Unaudited)

	As of March 31, 2026	As of September 30, 2026
	Millions of yen	Millions of yen
Assets		
Current assets		
Cash and cash equivalents	8,991	12,855
Trade and other receivables	496	511
Other financial assets	5,851	841
Inventories	1,092	1,058
Other current assets	124	169
Total current assets	16,553	15,434
Non-current assets		
Operating lease assets	318	341
Property, plant and equipment	13,022	12,891
Right of use assets	388	411
Goodwill	1,884	1,855
Intangible assets	35	30
Investments accounted for using equity method	234	231
Other financial assets	16,136	17,514
Deferred tax assets	510	500
Total non-current assets	32,528	33,774
Total assets	49,081	49,208

	As of March 31, 2026	As of September 30, 2026
	Millions of yen	Millions of yen
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	624	523
Bonds and borrowings	30	27
Lease liabilities	143	150
Other current liabilities	361	387
Total current liabilities	1,157	1,087
Non-current liabilities		
Bonds and borrowings	10	10
Third-party interests in CEJ Fund	5,249	4,982
Lease liabilities	284	301
Provisions	191	191
Deferred tax liabilities	2,536	2,761
Other non-current liabilities	46	46
Total non-current liabilities	8,315	8,290
Total liabilities	9,472	9,378
Equity		
Share capital	10	10
Capital surplus	42,322	42,322
Treasury shares	(1,188)	(1,188)
Other components of equity	(874)	(712)
Retained earnings	(648)	(588)
Total equity attributable to owners of the parent	39,622	39,845
Non-controlling interests	(13)	(14)
Total equity	39,609	39,831
Total liabilities and equity	49,081	49,208

(2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income (Unaudited)

Condensed year to quarter end consolidated statement of profit or loss

	Six months ended September 30, 2025	Six months ended September 30, 2026
	Millions of yen	Millions of yen
Revenue	1,963	2,008
Cost of sales	(742)	(832)
Gross profit	1,222	1,176
Selling, general and administrative expenses		
Research and development expenses	(437)	(366)
Other selling, general and administrative expenses	(1,187)	(1,175)
Total selling, general and administrative expenses	(1,625)	(1,541)
Other income	284	260
Other expenses	(55)	(20)
Operating profit (loss)	(174)	(124)
Finance income	627	410
Finance costs	(261)	(122)
Gains related to CEJ Fund	109	8
Share of profit (loss) of investments accounted for using equity method	(4)	(3)
Profit (loss) before tax	297	170
Income tax expense	(229)	(116)
Profit (loss)	68	53
Profit (loss) attributable to		
Owners of parent	70	54
Non-controlling interests	(3)	(1)
Profit (loss)	68	53
Earnings (loss) per share		
Basic earnings (loss) per share (yen)	0.33	0.26
Diluted earnings (loss) per share (yen)	0.33	0.26

Condensed year to quarter end consolidated statement of comprehensive income

	Six months ended September 30, 2025	Six months ended September 30, 2026
	Millions of yen	Millions of yen
Profit (loss)	68	53
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	(18)	(215)
Total of items that will not be reclassified to profit or loss	(18)	(215)
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	(25)	(46)
Total of items that may be reclassified to profit or loss	(25)	(46)
Total other comprehensive income, net of tax	(43)	168
Comprehensive income	25	222
Comprehensive income attributable to		
Owners of parent	27	223
Non-controlling interests	(3)	(1)
Comprehensive income	25	222

(3) Condensed quarterly consolidated statement of changes in equity (Unaudited)

Six months ended September 30, 2025 (from April 1, 2025 to September 30, 2025)

	Equity attributable to owners of parent					
				Other components of equity		
	Share capital	Capital surplus	Treasury shares	Financial assets measured at fair value through other comprehensive income	Exchange differences on translation of foreign operations	Stock acquisition rights
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
April 1, 2025	10	42,297	(1,188)	(1,261)	499	19
Profit (loss)	—	—	—	—	—	—
Other comprehensive income	—	—	—	(18)	(25)	—
Total comprehensive income	—	—	—	(18)	(25)	—
Acquisition of treasury shares	—	—	—	—	—	—
Forfeiture of share acquisition rights	—	—	—	—	—	(6)
Total transactions with owners	—	—	—	—	—	(6)
September 30, 2025	10	42,297	(1,188)	(1,280)	475	13

	Equity attributable to owners of parent			Non-controlling interests	Total equity
	Other components of equity	Retained earnings	Total		
	Total				
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
April 1, 2025	(743)	(801)	39,575	18	39,593
Profit (loss)	—	70	70	(3)	68
Other comprehensive income	(43)	—	(43)	—	(43)
Total comprehensive income	(43)	70	27	(3)	25
Acquisition of treasury shares	—	—	—	—	—
Forfeiture of share acquisition rights	(6)	—	(6)	—	(6)
Total transactions with owners	(6)	—	(6)	—	(6)
September 30, 2025	(792)	(731)	39,596	16	39,612

Six months ended September 30, 2026 (from April 1, 2026 to September 30, 2026)

	Equity attributable to owners of parent					
				Other components of equity		
	Share capital	Capital surplus	Treasury shares	Financial assets measured at fair value through other comprehensive income	Exchange differences on translation of foreign operations	Stock acquisition rights
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
April 1, 2026	10	42,322	(1,188)	(1,470)	583	13
Profit (loss)	—	—	—	—	—	—
Other comprehensive income	—	—	—	( )	(46)	—
Total comprehensive income	—	—	—	( )	(46)	—
Acquisition of treasury shares	—	—	(0)	—	—	—
Forfeiture of share acquisition rights	—	—	—	—	—	(6)
Total transactions with owners	—	—	(0)	—	—	(6)
September 30, 2026	10	42,322	(1,188)	( )	537	7

	Equity attributable to owners of parent			Non-controlling interests	Total equity
	Other components of equity	Retained earnings	Total		
	Total				
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
April 1, 2026	(874)	(648)	39,622	(13)	39,609
Profit (loss)	—	54	54	(1)	53
Other comprehensive income	168	—	168	—	(168)
Total comprehensive income	168	54	223	(1)	222
Acquisition of treasury shares	—	—	(0)	—	(0)
Forfeiture of share acquisition rights	(6)	6	—	—	—
Total transactions with owners	(6)	6	(0)	—	(0)
September 30, 2026	(712)	(588)	39,845	(14)	39,831

(4) Condensed quarterly consolidated statement of cash flows (Unaudited)

	Six months ended September 30, 2025	Six months ended September 30, 2026
	Millions of yen	Millions of yen
Cash flows from operating activities		
Profit (loss) before tax	297	170
Depreciation and amortization	308	307
Finance income	(627)	(410)
Finance costs	261	122
Loss (gains) on CEJ Fund	(109)	(8)
Share of loss (profit) of investments accounted for using equity method	4	3
Decrease (increase) in inventories	(98)	34
Decrease (increase) in trade and other receivables	321	(16)
Increase (decrease) in trade and other payables	59	(100)
Other	(75)	(194)
Subtotal	341	(93)
Interest received	23	52
Interest paid	(0)	(0)
Income taxes paid	(2)	(4)
Income taxes refund	—	1
Net cash provided by (used in) operating activities	362	(44)
Cash flows from investing activities		
Purchase of investments	(10,000)	—
Proceeds of redemption of investments	7,984	5,000
Payments into time deposits	(744)	(240)
Purchase of property, plant and equipment	(11)	(10)
Purchase of investment securities	(30)	(833)
Proceeds from Sale of Investment Securities	—	137
Payments for loans receivable	(2)	—
Collection of loans receivable	9	9
Other	1	(0)
Net cash provided by (used in) investing activities	(2,794)	(4,063)
Cash flows from financing activities		
Repayments of long-term borrowings	(3)	(3)
Repayments of lease obligation	(85)	(97)
Dividends paid to non-controlling interests	—	(30)
Other	(9)	(16)
Net cash provided by (used in) financing activities	(97)	(146)
Effect of exchange rate changes on cash and cash equivalents	15	(8)
Net increase (decrease) in cash and cash equivalents	(2,513)	(3,865)
Cash and cash equivalents at beginning of fiscal year	6,824	8,991
Cash and cash equivalents at end of year	4,311	12,855

(5) Notes to condensed quarterly consolidated financial statements

(Notes on premise of going concern)

There are no items to report.

(Segment information)

(1) Service transferred over time

The Group's reportable segments are the components of the Group for which discrete financial information is available and which are regularly reviewed by the Board of Directors in deciding how to allocate resources and assess their performance. Since the Group operates under a single segment of business related to robotics, segment information is omitted.

(2) Revenue and results of reportable segments

Since the Group operates under a single segment, segment information is omitted.

(3) Information about Products and Services

Please refer to the Note "Revenue" for information related to products and services.

(Revenue)

Disaggregation of revenue

Details of disaggregation of revenue are set forth below.

	Six months ended September 30, 2025	Six months ended September 30, 2026
	Millions of yen	Millions of yen
Timing of revenue recognition		
Service transferred over time	939	934
Asset transferred at a point of time	168	108
Service transferred at a point of time	856	966
Total	1,963	2,008

(Note) Since the Group operates under a single segment of business, segment information on revenue is omitted.

Service transferred over time

Service transferred over time includes rental income based on the individual rental contract, maintenance income based on the maintenance contract concerning finance lease income where the Group acts as a lessor of right-of-use asset and subscription fees from the provision and operation of smartphone applications.

The Group recognizes rental income as income generated throughout the rental period after the customer accepts the relevant product by either of the following methods. Pay-per-use model based on times of product usage in the applicable month or base fee model based on the fixed monthly price.

The Group recognizes maintenance income as a performance obligation satisfied over time. Accordingly, the Company records this revenue during this contract period based on the average amount during the period.

The Group recognizes subscription fees for the provision and operation of smartphone applications as service provided through an application over time. The Company records this revenue over time.

Asset transferred at a point of time

The asset transferred at a point of time includes revenue from sales of commodities and products based on the sales contract. The Group mainly determines that performance obligation of sales of commodities and products are satisfied at the point of customer acceptance of the relevant product. Therefore, the Group receives most of the payment within one month from the point of fulfilling the performance obligation. Regarding transaction price, there is no significance in the amount of sales revenue that includes variable consideration. Furthermore, there are no significant financial components in the amount of promised consideration.

Furthermore, if the Group acts as a lessor of right-of-use of its devices such as HAL, the Group classifies the relevant lease as a finance lease. Finance lease income is processed in the same way as cases where the Group acts as a lessor of manufacturer or distributor of sales of goods. The Group determines that performance obligation is satisfied at the point of customer acceptance, and the revenue is recognized at a point of time.

Service transferred at a point of time

Service transferred at a point of time includes revenue from offering Cybernic Treatment and training service at Cybernic Treatment Center and Robocare Centers to end-users (such as patients). In addition, the Company also includes revenue received in return for providing outcomes of consigned research projects in this category.

The Group determines that the performance obligation of Cybernic Treatment and training services are satisfied at the point of completion of such services. Furthermore, the Group determines that the performance obligation of providing outcomes of consigned research projects is satisfied when the customer inspects and accepts the work.